Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News and Views
Nature Medicine 15, 732–733 (1 July 2009) | doi:10.1038/nm0709-732
Targeting lymphotoxin depletes pathogenic T cells
&
Abstract
Over the last ten years, the treatment options for individuals with autoimmune disorders have improved dramatically. A range of protein-based therapeutic agents have entered the market that specifically target the signaling pathways that cause conditions such as rheumatoid arthritis and multiple sclerosis.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
